BOT+BAL yield three-year survival in 48% of patients with recurrent ovarian cancer, phase Ib study finds

Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits

After a decade of litigation, Johnson and Johsnon has agreed to a settlement deal to resolve the some 69,000 lawsuits alleging the company’s talc-based baby powder caused ovarian cancer and mesothelioma.

August 07, 2026

Vol.52 No.31

By Claire Marie Porter

Clinical Roundup

Chemo resistance in ovarian cancer may be reversible with existing drugs, Wistar study finds

Scientists at The Wistar Institute have identified a mechanism behind the chemotherapy resistance that makes ovarian cancer so lethal. The researchers showed that chemotherapy triggers an inflammatory cascade that recruits immune cells into the tumor microenvironment, which ultimately function to protect the cancer from subsequent chemotherapy.

July 24, 2026

Vol.52 No.29

Clinical Roundup

Ovarian cancer cells use stress hormone signaling to shut down immune system, UTSW study finds

When activated in ovarian cancer cells, the receptor for the body’s primary stress hormone alters the tumor environment in ways that blunt immune response, according to research led by UT Southwestern Medical Center.

May 29, 2026

Vol.52 No.21

In Brief

Ovarian Cancer Research Alliance launches a global AI-powered ecosystem to accelerate gynecologic cancer research

Ovarian Cancer Research Alliance announced the launch of the Community Accelerated Research Exchange, a first-of-its-kind, global, AI-powered ecosystem designed to transform how gynecologic cancer research is conducted—accelerating breakthroughs by connecting patients, clinicians, researchers, and advocates in real time.

May 15, 2026

Vol.52 No.19

Drugs & Targets

FDA grants Fast Track designation for lunresertib + zedoresertib for genomic-defined platinum-resistant ovarian cancer

FDA granted Fast Track designation to Debiopharm for the use of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123) for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer.

April 24, 2026

Vol.52 No.16

Clinical Roundup

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

Adding IMNN-001, a DNA-mediated immunotherapy, to standard-of-care treatment improved median overall survival by 14.7 months in patients with newly diagnosed advanced ovarian cancer, final clinical data from the OVATION 2 study shows.

April 03, 2026

Vol.52 No.13

BOT+BAL yield three-year survival in 48% of patients with recurrent ovarian cancer, phase Ib study finds

YOU MAY BE INTERESTED IN

Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits

Chemo resistance in ovarian cancer may be reversible with existing drugs, Wistar study finds

Ovarian cancer cells use stress hormone signaling to shut down immune system, UTSW study finds

Ovarian Cancer Research Alliance launches a global AI-powered ecosystem to accelerate gynecologic cancer research

FDA grants Fast Track designation for lunresertib + zedoresertib for genomic-defined platinum-resistant ovarian cancer

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

Renew today!

Subscriber content

Never miss an issue!

Login